A Phase II Non-blinded Randomized Study Comparing External Beam Radiotherapy (EBRT), 177Lu-PSMA-617, and Short Term Androgen Deprivation Therapy (ADT) Versus EBRT and Long Term ADT in Men With High Risk Localized Prostate Cancer
Latest Information Update: 30 Apr 2026
At a glance
- Drugs Lutetium (177Lu) vipivotide tetraxetan (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
Most Recent Events
- 30 Apr 2026 New trial record